Get the Stockscreener App
84.38
0.54%
-0.46
After Hours:
84.00
-0.38
-0.45%
Dexcom Inc stock is traded at $84.38, with a volume of 5.06M.
It is down -0.54% in the last 24 hours and up +8.46% over the past month.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$84.84
Open:
$86.32
24h Volume:
5.06M
Relative Volume:
1.32
Market Cap:
$33.81B
Revenue:
$3.95B
Net Income/Loss:
$680.80M
P/E Ratio:
50.53
EPS:
1.67
Net Cash Flow:
$535.00M
1W Performance:
+8.51%
1M Performance:
+8.46%
6M Performance:
-26.38%
1Y Performance:
-32.74%
1-Day Range:
$83.89
$86.33
1-Week Range:
$73.62
$86.33
52-Week Range:
$62.34
$142.00
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
84.38 | 33.81B | 3.95B | 680.80M | 535.00M | 1.67 |
|
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Top 10 Medical Device Predictions for 2025 - GlobeNewswire Inc.
Wealthcare Advisory Partners LLC Has $998,000 Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Gateway Investment Advisers LLC - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Sees Significant Decline in Short Interest - MarketBeat
DexCom raised to outperform by Baird - MSN
Dexcom inks glucose biosensor partnership with Life Time - Drug Delivery Business News
DexCom (NASDAQ:DXCM) shareholder returns have been decent, earning 44% in 5 years - Yahoo Finance
DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Sax Wealth Advisors LLC - MarketBeat
Avanza Fonder AB Takes Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Legacy Wealth Asset Management LLC Acquires New Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback - Seeking Alpha
Woodstock Corp Cuts Holdings in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom (NASDAQ:DXCM) Stock Price Up 3.7%Here's What Happened - MarketBeat
JPM25 recap: Robotics, PFA and OTC glucose sensors in the spotlight - MedTech Dive
Baird R W Upgrades DexCom (NASDAQ:DXCM) to Strong-Buy - MarketBeat
Latin America Continuous Glucose Monitoring Device Market Projected To Witness Substantial Growth, - EIN News
Fifth Third Wealth Advisors LLC Has $477,000 Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Oak Thistle LLC - MarketBeat
DexCom (NASDAQ:DXCM) Stock Unloaded Rep. Kevin Hern - MarketBeat
DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook - MSN
Why DexCom, Inc. (DXCM) Is Skyrocketing - Insider Monkey
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom raised to outperform by Baird (DXCM:NASDAQ) - Seeking Alpha
Piper Sandler bullish on DexCom shares citing growth potential and new catalysts - MSN
Baird raises DexCom stock to outperform, target to $104 - MSN
Expert Outlook: DexCom Through The Eyes Of 11 Analysts - Benzinga
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Outlook Wealth Advisors LLC Buys New Stake in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom (NASDAQ:DXCM) Upgraded by Robert W. Baird to Outperform Rating - MarketBeat
2 Healthcare Stocks to Buy Hand Over Fist in January - Yahoo Finance
DexCom, Inc. (NASDAQ:DXCM) Holdings Decreased by Assenagon Asset Management S.A. - MarketBeat
180 Wealth Advisors LLC Invests $255,000 in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Dexcom CEO talks Stelo sensor launch, OTC strategy - MedTech Dive
Earnings Summary: DexCom reports preliminary Q4 2024 results - AlphaStreet
JP Morgan 2025: Dexcom shares up 5% after 2025 outlook forecasts $4.6bn in revenue - Yahoo Finance
DexCom revenue increases 8% in Q4 2024 - Medical Buyer
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - MSN
DexCom (NASDAQ:DXCM) Shares Gap UpShould You Buy? - MarketBeat
CHICAGO TRUST Co NA Grows Stock Holdings in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom stock rises on 2025 outlook - MSN
DexCom stock gains, sees 14% revenue growth in 2025 By Investing.com - Investing.com Canada
DexCom stock gains, sees 14% revenue growth in 2025 - Investing.com India
DexCom stock rises on 2025 outlook (NASDAQ:DXCM) - Seeking Alpha
DexCom Q4 Revenue Hits $1.1B as International Sales Surge 17%, Sets Ambitious 2025 Growth Target - StockTitan
DexCom price target raised to $89 from $86 at Bernstein - MSN
Abbott, Dexcom End UPC Feud Over Glucose Monitor Patent - Law360
DexCom (NASDAQ:DXCM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
42,021 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Watts Gwilliam & Co. LLC - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by First Hawaiian Bank - MarketBeat
Diversified Trust Co Lowers Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Why Is Jim Cramer Mystified by DexCom, Inc. (DXCM)’s Earnings Miss and Competitive Challenges? - Insider Monkey
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):